About Laevoroc Oncology
Laevoroc Oncology is a company based in Hunenberg (Switzerland) founded in 2019 by Davide Guggi. Laevoroc Oncology has raised $1.1 million across 1 funding round. Laevoroc Oncology offers products and services including LR09, LR06, and LR02. Laevoroc Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Hunenberg, Switzerland
- Founders Davide Guggi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Laevoroc Oncology Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.1 M (USD)
in 1 rounds
-
Latest Funding Round
$1.1 M (USD), Seed
May 11, 2021
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Laevoroc Oncology
Laevoroc Oncology offers a comprehensive portfolio of products and services, including LR09, LR06, and LR02.
Inhibitor targeting relapsed leukemia after stem cell transplantation
Oral prodrug for maintenance therapy in various cancers
Inhibitor for brain cancer treatment with CNS penetration
People of Laevoroc Oncology
Unlock access to complete
Unlock access to complete
Funding Insights of Laevoroc Oncology
Laevoroc Oncology has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.1 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Laevoroc Oncology
Investment portfolio details for Laevoroc Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Laevoroc Oncology
Detailed financials for Laevoroc Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Laevoroc Oncology Comparisons
Peer comparison for Laevoroc Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Laevoroc Oncology
Laevoroc Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Laevoroc Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Laevoroc Oncology
Complete news archive for Laevoroc Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laevoroc Oncology
Laevoroc Oncology was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Laevoroc Oncology is headquartered in Hunenberg, Switzerland. It is registered at Hunenberg, Zug, Switzerland.
Laevoroc Oncology is a funded company, having raised a total of $1.1M across 1 funding round to date.
Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.
Laevoroc Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Laevoroc Oncology offers LR09, LR06, and LR02.